BeOne Medicines annual ebitda margin
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BeOne Medicines EBITDA Margin Growth & History (ONC)
BeOne Medicines's ebitda margin was 11.02% for fiscal 2025.
View full BeOne Medicines company overviewBeOne Medicines annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 11.02% | +21.42 pp |
| 2024 | 2024-12-31 | −10.40% | +35.15 pp |
| 2023 | 2023-12-31 | −45.55% | +76.16 pp |
| 2022 | 2022-12-31 | −121.71% | −3.35 pp |
| 2021 | 2021-12-31 | −118.36% | +408.03 pp |
| 2020 | 2020-12-31 | −526.39% | −306.58 pp |
| 2019 | 2019-12-31 | −219.81% | +131.00 pp |
| 2018 | 2018-12-31 | −350.81% | −311.51 pp |
| 2017 | 2017-12-31 | −39.31% | +10722.47 pp |
| 2016 | 2016-12-31 | −10,761.78% | −10135.64 pp |
| 2015 | 2015-12-31 | −626.13% | −517.20 pp |
| 2014 | 2014-12-31 | −108.94% | — |
BeOne Medicines quarterly ebitda margin
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 21.44% | +12.05 pp |
| Q1 2026 | 2026-03-31 | 19.23% | +15.30 pp |
| Q4 2025 | 2025-12-31 | 14.75% | +17.34 pp |
| Q3 2025 | 2025-09-30 | 14.19% | +19.08 pp |
| Q2 2025 | 2025-06-30 | 9.39% | +18.24 pp |
| Q1 2025 | 2025-03-31 | 3.93% | +35.33 pp |
| Q4 2024 | 2024-12-31 | −2.59% | +54.15 pp |
| Q3 2024 | 2024-09-30 | −4.89% | +9.50 pp |
| Q2 2024 | 2024-06-30 | −8.85% | +40.94 pp |
| Q1 2024 | 2024-03-31 | −31.40% | +47.03 pp |
| Q4 2023 | 2023-12-31 | −56.74% | +61.81 pp |
| Q3 2023 | 2023-09-30 | −14.39% | +94.51 pp |
| Q2 2023 | 2023-06-30 | −49.79% | +74.32 pp |
| Q1 2023 | 2023-03-31 | −78.44% | +60.72 pp |
| Q4 2022 | 2022-12-31 | −118.55% | +142.51 pp |
| Q3 2022 | 2022-09-30 | −108.91% | +109.15 pp |
| Q2 2022 | 2022-06-30 | −124.11% | +184.78 pp |
| Q1 2022 | 2022-03-31 | −139.16% | −152.33 pp |
| Q4 2021 | 2021-12-31 | −261.06% | +215.55 pp |
| Q3 2021 | 2021-09-30 | −218.05% | +256.03 pp |
| Q2 2021 | 2021-06-30 | −308.89% | +225.90 pp |
| Q1 2021 | 2021-03-31 | 13.17% | +716.23 pp |
| Q4 2020 | 2020-12-31 | −476.61% | +192.30 pp |
| Q3 2020 | 2020-09-30 | −474.08% | +140.67 pp |
| Q2 2020 | 2020-06-30 | −534.79% | −501.04 pp |
| Q1 2020 | 2020-03-31 | −703.06% | −484.21 pp |
| Q4 2019 | 2019-12-31 | −668.90% | −196.01 pp |
| Q3 2019 | 2019-09-30 | −614.75% | −340.49 pp |
| Q2 2019 | 2019-06-30 | −33.75% | +270.61 pp |
| Q1 2019 | 2019-03-31 | −218.85% | +114.74 pp |
| Q4 2018 | 2018-12-31 | −472.89% | +86.94 pp |
| Q3 2018 | 2018-09-30 | −274.26% | −327.03 pp |
| Q2 2018 | 2018-06-30 | −304.36% | — |
| Q1 2018 | 2018-03-31 | −333.59% | — |
| Q4 2017 | 2017-12-31 | −559.83% | — |
| Q3 2017 | 2017-09-30 | 52.77% | — |
| Q2 2016 | 2016-06-30 | −6,141.48% | −5692.78 pp |
| Q1 2016 | 2016-03-31 | −2,938.70% | −2252.70 pp |
| Q4 2015 | 2015-12-31 | −555.01% | — |
| Q3 2015 | 2015-09-30 | −984.78% | — |
| Q2 2015 | 2015-06-30 | −448.70% | — |
| Q1 2015 | 2015-03-31 | −686.00% | — |
BeOne Medicines ebitda margin trends
Over the last five fiscal years, BeOne Medicines's ebitda margin increased from −526.39% to 11.02%, a change of +537.41 percentage points. The latest reported quarter, Q2 2026, shows 21.44%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BeOne Medicines source filings ↗Community posts
BeOne’s initial clinical results support planned late-stage studies
BeOne Medicines ($ONC) disclosed new dose-optimization findings for BGB-B2033 in heavily pretreated liver cancer. At the proposed Phase 3 dose, the bispecific antibody produced confirmed responses in 36% of patients, with an estimated 74.1% ...
